NASDAQ$ZYXIQ

Zynex Inc · Q1 2020 earnings

Q1 2020 earnings · · Investor relations

Briefing

Reported a 66% increase in revenue and a net income of $2.9 million.

Zynex reported a strong first quarter with a 66% increase in revenue to $15.2 million and a net income of $2.9 million, marking the fifteenth consecutive quarter of positive net income. The company also saw significant order growth and generated $0.6 million in cash from operations.

  • Net revenue increased by 66% compared to the first quarter of 2019.
  • Net income reached $2.9 million.
  • Orders grew 126% compared to the first quarter of 2019.
  • Cash from operations was $0.6 million.

Headline financials

Total Revenue

$15.2M

Previous: $9.2M+65.6%
EPS (adj)

$0.08

Previous: $0.06+33.3%
Adjusted EBITDA

$3M

No prior period
Capital Expenditures

-$297K

Previous: -$46K-545.7%
Free Cash Flow

$335K

Previous: $1.72M-80.5%
Net Income

$2.94M

Previous: $2.35M+25.0%
Operating Income

$2.46M

Previous: $2.26M+9.0%
Gross Profit

$11.8M

Previous: $7.41M+59.6%
Cash & Equivalents

$14.6M

Previous: $9.42M+54.8%
Total Assets

$33.2M

Previous: $18.9M+76.1%
Stock-Based Comp

$497K

Previous: $140K+255.0%

Revenue & EPS history

Zynex · Revenue · Quarterly

$15.2M

Q1 2020+65.6%vs Q1 2019
Beat estimate in 12 of 14 quarters(86%)
ActualEstimate

Revenue by segment

Zynex · $49.9M total across 2 segments · Q3 2023

  • Supplies
    $33.1M
  • Devices
    $16.9M

Forward guidance

The estimated range for second quarter revenue is between $17.5 and $18.0 million with Adjusted EBITDA between $3.2 and $3.7 million as we continue to invest in growing our sales force. Full year 2020 estimates are unchanged. Revenue is estimated between $78.0 and $83.0 million with Adjusted EBITDA between $15.0 and $18.0 million.

Tailwinds

  • Second quarter revenue is expected to be between $17.5 and $18.0 million.
  • Adjusted EBITDA for the second quarter is projected to be between $3.2 and $3.7 million.
  • Full year revenue is estimated between $78.0 and $83.0 million.
  • Full year Adjusted EBITDA is projected to be between $15.0 and $18.0 million.
  • Order volumes have stabilized and remained steady during the last 3 weeks of March and through April.

Headwinds

  • The COVID-19 pandemic continues to impact the availability of physicians to prescribe products.
  • Employee and supply chain issues are being navigated due to COVID-19.
  • Second quarter revenue estimate is approximately 70% to 75% above 2019 second quarter revenue of $10.3 million.
  • Full year revenue estimate is approximately 72% to 83% above 2019 revenue of $45.5 million.
  • The company continues to invest in growing its sales force.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports

Historical avg

+0.4%

Avg return

Earnings day

-1.8%

Avg return

5 days after

-6.5%

Avg return

30 days after

46%

29 / 63 earnings

Positive

+38.5%

Q3 2014

Best reaction

-51.6%

Q1 2010

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2024-51.3%
Q3 2025+0.0%+0.0%-98.2%
Q2 2025+0.0%+0.0%+0.0%
Q1 2025-25.6%+0.0%+0.0%
Q3 2024+9.1%+0.0%+0.0%
Q2 2024-11.4%+0.0%+0.0%
Q1 2024+2.8%+0.0%+0.0%
Q4 2023-8.8%+0.0%+0.0%
Q3 2023+17.5%+0.0%+0.0%
Q2 2023+3.3%+0.0%+0.0%
Q1 2023+2.5%+0.0%+0.0%
Q4 2022+16.7%+0.0%+0.0%
Q3 2022+15.0%+0.0%+0.0%
Q2 2022+13.3%+0.0%+0.0%
Q1 2022-8.6%+0.0%+0.0%
Q4 2021-1.7%+0.0%+0.0%
Q3 2021+10.0%+0.0%+0.0%
Q2 2021-19.3%+0.0%+0.0%
Q1 2021-9.2%-12.0%-6.3%
Q4 2020-21.2%-22.4%-18.8%
Q3 2020-6.5%
Q2 2020-6.0%
Q1 2020-1.1%
Q4 2019+3.1%
Q3 2019-7.9%
Q2 2019+9.8%
Q1 2019+7.9%
Q4 2018-11.1%
Q3 2018+3.4%
Q2 2018-3.3%
Q1 2018+4.5%
Q4 2017-20.7%
Q3 2017+6.6%
Q2 2017+34.6%
Q1 2017-5.6%
Q4 2016+9.7%
Q3 2016+23.1%
Q2 2016+34.8%
Q1 2016+0.0%
Q4 2015+0.0%
Q3 2015-4.3%
Q2 2015-5.4%
Q4 2014+0.0%
Q1 2015+0.0%
Q3 2014+38.5%
Q2 2014+2.2%
Q1 2014-0.2%
Q4 2013-3.6%
Q3 2013+13.6%
Q2 2013+7.1%
Q1 2013+0.0%
Q4 2012+3.4%
Q3 2012+5.6%
Q2 2012-5.1%
Q1 2012-6.3%
Q4 2011+0.0%
Q3 2010+12.9%
Q3 2011+12.9%
Q2 2011+1.1%
Q1 2011-8.2%
Q4 2010+0.0%
Q2 2010+2.0%
Q1 2010-51.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro